AstraZeneca, H1 2020: performance underpins leading response to COVID19.

Alleen voor leden beschikbaar, wordt daarom gratis lid!

01/08/2020 06:55
Key highlights
Total revenue up by 14%; modest benefit from COVID 19 1 stocking
revenue performance : new medicines (+ 2 ; Oncology (+31%), New CVRM 3 (+11%), Respiratory & Immunology
(+7%) and Emerging markets (+
operating profit up by 23% despite lower OOI 4 13%)
Core EPS 5 $2.01 (+26%), including stable 21% tax rate
saw continued progress, in particular regulatory approvals, supporting future growth

see &
Leading response to the
COVID 19 pandemic: advancing a prominent vaccine candidate while repositioning other
medicines; additional focus on patient access, supply of existing medicines, employee safety, and work continuity
Guidance unchanged
: Total revenue expected to increase by a high single digit to a low double digit percentage and core
EPS expected to increase by a mid to high teens percentage
H1 2020: performance underpins leading response to COVID19
Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for H1 2020, unless otherwise stated.
Gui dance at CER. 1. The infectious disease caused by the most recently discovered coronavirus SARS CoV 2 2. Total revenue for Tagrisso
Imfinzi , Lynparza , Enhertu , Calquence , Koselugo , Farxiga , Brilinta , Lokelma , roxadustat, Fasenra , Bevespi and Breztri 3. New Cardiovascular, Renal and Metabolism comprising Brilinta , Renal and Diabetes 4. Other operating income 5. Earnings per

Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord

Copyrights © 2000 by all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.